secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001689548-24-000086
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis reports Q2 2024 net loss $32.7M; cash $433.8M; multiple trial milestones on track
--------------------------------------------------------------------------------

- Cash and investments $433.8M ($81.3M at Dec 31, 2023); runway into 2027.
- Net loss $32.7M vs $34.3M YoY; R&D expense $27.3M vs $25.6M.
- Ulixacaltamide Essential3 interim analysis in Q4 2024; NDA submission on track for 2025.
- Relutrigine (PRAX-562) Phase 2 EMBOLD topline results expected Q3 2024.
- PRAX-628 Phase 2/3 POWER1 study to start Q4 2024; RADIANT Phase 2 topline H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954824000086/0001689548-24-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954824000086/prax-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001689548-24-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer